What are the mechanism of action, elimination half‑life, interactions with P‑glycoprotein and cytochrome P450 2D6, effects on the QT interval, and effects on cardiac conduction of propranolol?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Propranolol: Pharmacological Profile

Propranolol is a nonselective beta-adrenergic receptor antagonist that blocks both β1 and β2 receptors, slowing AV nodal conduction and reducing heart rate, with extensive hepatic metabolism primarily via CYP2D6, minimal QT effects, and significant cardiac conduction slowing effects. 1

Mechanism of Action

Propranolol competitively blocks beta-adrenergic receptor sites, decreasing chronotropic (heart rate), inotropic (contractility), and vasodilator responses to beta-adrenergic stimulation 1. The drug acts by:

  • Antagonizing sympathetic tone in nodal tissue, resulting in slowing of AV nodal conduction 2
  • Reducing cardiac output as a primary antihypertensive mechanism
  • Inhibiting renin release by the kidneys
  • Diminishing tonic sympathetic outflow from vasomotor centers in the brain 1

At higher doses, propranolol exhibits a quinidine-like or anesthetic-like membrane action affecting the cardiac action potential, though the clinical significance of this effect in treating arrhythmias remains uncertain 1.

Elimination Half-Life

The elimination half-life of propranolol is approximately 3-6 hours in healthy subjects 1. However, this can be significantly prolonged in patients with hepatic impairment—increasing to 7.2 hours in cirrhotic patients compared to 2.9 hours in controls 1.

Important clinical consideration: The half-life is not significantly different between CYP2D6 extensive metabolizers and poor metabolizers 3, though metabolite profiles differ substantially.

P-glycoprotein Interactions

Propranolol is a substrate of the intestinal efflux transporter P-glycoprotein (P-gp) 1. However, studies suggest that P-gp is not dose-limiting for intestinal absorption of propranolol in the usual therapeutic dose range 1.

More importantly, propranolol significantly inhibits P-glycoprotein function with an IC50 of 24.8 μM for digoxin transport 4. This creates potential for clinically relevant drug interactions, particularly with:

  • Digoxin: Propranolol can increase digoxin levels through P-gp inhibition
  • Cyclosporine: Potential interaction through P-gp mechanism 4

CYP2D6 Interactions

Propranolol is extensively metabolized by CYP2D6, which catalyzes approximately 65-70% of its 4-hydroxylation pathway 3. The drug undergoes three primary metabolic routes 1:

  1. Aromatic hydroxylation (mainly 4-hydroxylation): 42% of metabolism, primarily via CYP2D6
  2. N-dealkylation followed by side-chain oxidation: 41% of metabolism, mediated by CYP1A2 and CYP2D6
  3. Direct glucuronidation: 17% of metabolism

Critical Drug Interactions via CYP2D6

Propranolol acts as a mechanism-based inhibitor of CYP2D6 5, meaning it irreversibly inactivates the enzyme. This creates significant interaction potential:

  • Quinidine co-administration results in a doubling of propranolol AUC (530 vs 1051 ng·hr/mL) and reduces clearance from 3087 to 1378 mL/min 6. The 4-hydroxylation pathway is almost completely abolished (678 to 56 mL/min) 6.

  • Other CYP2D6 inhibitors that increase propranolol levels include: amiodarone, cimetidine, fluoxetine, paroxetine, and ritonavir 1

  • CYP2D6 poor metabolizer phenotype does not significantly alter propranolol blood concentrations or clinical response 3, likely because alternative metabolic pathways compensate.

Propranolol as a CYP2D6 Inhibitor

When propranolol inhibits CYP2D6, it can increase levels of other CYP2D6 substrates, though this is less clinically significant than with metoprolol 7.

Effects on QT Interval

Propranolol has minimal direct effects on the QT interval 8. This is a critical distinguishing feature from other beta-blockers like sotalol:

  • Beta-blockers minimally alter the absolute QT interval, especially at heart rates of 60-100 bpm 8
  • Propranolol is recommended for use in congenital long QT syndrome precisely because it does not prolong the QT interval 8, 9
  • Nonselective beta-blockers like propranolol and nadolol confer greater protection in long QT syndrome compared to β1-selective agents 8, 9

Important Caveat

When propranolol is combined with quinidine, the interaction results in prolongation of the QTc interval 6, but this is due to quinidine's direct effect rather than propranolol itself.

Effects on Cardiac Conduction

Propranolol significantly slows cardiac conduction through the AV node 2. This manifests as:

  • Bradycardia: Dose-dependent reduction in heart rate
  • AV conduction delays: Can progress to heart block
  • PR interval prolongation: When combined with other AV nodal blocking agents 6

Clinical Implications for Cardiac Conduction

Profound bradycardia can develop when propranolol is combined with other AV nodal blocking agents (calcium channel blockers, digoxin) due to overlapping effects from their longer half-lives 2. The guideline specifically warns against serial administration of these agents.

Contraindications related to conduction include 2:

  • Sinus bradycardia
  • Greater than first-degree heart block
  • Cardiogenic shock
  • Heart failure with reduced ejection fraction

Special Consideration: Pre-excited Atrial Fibrillation

AV nodal blocking drugs including propranolol should NOT be used for pre-excited atrial fibrillation or flutter (Class III recommendation) 2, as they may paradoxically accelerate the ventricular response through the accessory pathway.

Key Clinical Pearls

  • Propranolol is preferred over β1-selective agents (metoprolol, atenolol) for long QT syndrome due to superior efficacy 8, 9
  • Extensive hepatic metabolism means propranolol is not dialyzable 10, 1
  • CYP2D6 phenotype does not require dose adjustment due to compensatory metabolic pathways 3
  • Monitor for drug interactions particularly with CYP2D6 inhibitors and P-gp substrates like digoxin 1, 4
  • Avoid combining with other AV nodal blockers due to risk of profound bradycardia 2

References

Related Questions

Which beta‑blockers are not metabolized by CYP2D6 and can be safely used in a CYP2D6 intermediate metabolizer (*41/*41) who is taking bupropion, a strong CYP2D6 inhibitor?
What are the mechanism of action, half‑life, interactions with P‑glycoprotein and CYP2D6, effect on QT interval, and effect on cardiac conduction of Sublocade (extended‑release buprenorphine)?
What are the clinical implications and recommended drug dosing adjustments for patients who are genetically fast (ultra‑rapid) metabolizers of enzymes such as CYP2D6, CYP1A2, CYP3A5, NAT2, or UDP‑glucuronosyltransferases?
In a patient who is an intermediate metabolizer (CYP2D6 *41/*41), how does duloxetine affect CYP2D6 activity and which beta‑blocker is recommended for tachycardia?
Should short‑acting propranolol be taken on an empty stomach after radioactive iodine therapy, and does extended‑release propranolol require administration with food?
What is the appropriate ivermectin dosage (200 µg/kg) for a 70‑kg adult and a 20‑kg child, including repeat dosing for immunocompromised or severe cases and the addition of albendazole (400 mg) for hyperinfection?
What are the mechanism of action, elimination half‑life, interactions with P‑glycoprotein and CYP2D6, effects on the QT interval, and effects on cardiac conduction of midazolam (Versed)?
How long does it take a 2 mg dose of dexamethasone (Decadron) to be cleared from the body?
How should I urgently evaluate and manage pleuritic chest pain in a patient with systemic lupus erythematosus and a history of myocarditis?
What are the indications for using the Verbal Behavior Milestones Assessment and Placement (VB-MAPP) in behavioral therapy for children, and what are the specific assessment domains?
What is the appropriate evaluation and management for a patient with a prolonged QT interval and sinus bradycardia on a 12‑lead electrocardiogram?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.